Index of Articles From HIV i-Base

About HIV i-Base

Articles

• AIDS 2012: Human Rights, Access to Treatment, Activism and Politics (August 1, 2012)
• AIDS 2012: New Drugs and Formulations (August 1, 2012)
• AIDS 2012: Other Treatment Studies (August 1, 2012)
• Publications Launched at IAS 2012 (August 1, 2012)
• AIDS 2012: Four Ways to Find a Cure (August 1, 2012)
• Introduction to AIDS 2012 (August 1, 2012)
• HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps Between Scientific Promise and Program Delivery (July 21, 2012)
  Recent advances in biomedical HIV, hepatitis C virus (HCV) and tuberculosis (TB) prevention and treatment are not reaching those who need them most; political leaders continue to break domestic, global health commitments.
• 2012 Pipeline Report: HIV, Hepatitis C Virus (HCV) and Tuberculosis Drugs, Diagnostics, Vaccines and Preventive Technologies in Development (PDF) (July 2012)
• New BHIVA Guidelines: HIV-Positive Adults and HIV & Pregnancy (May 8, 2012)
• Avoiding and Managing Side Effects (May 2008)
• Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)

Booklets

• HIV and Your Quality of Life: A Guide to Side Effects and Other Complications (July 2012)
  To read PDF, click here.
• An Introduction to Combination Therapy (PDF) (April 2012)
  An easy-to-read guide from the United Kingdom on what questions to ask, how to talk to your doctor, and the difference between various anti-HIV drugs and combinations.
• Antiretroviral Pill Chart (PDF) (April 2012)
  In An Introduction to Combination Therapy
• HIV Testing and Risks of Sexual Transmission (February 2012)
  To read PDF, click here.
• Guide to HIV, Pregnancy and Women's Health (September 2011)
  To read PDF, click here.
• Changing Treatment and Drug Resistance (February 2011)
  To read PDF, click here.
• Hepatitis C for People Living With HIV (March 2009)
  Testing, coinfection, treatment and support.
  To read PDF, click here.

HIV Treatment Bulletin

• WHO Statement: Generic Antiretroviral Therapy Is Safe and Effective (January/February 2013)
  To read PDF, click here.
• Nevirapine-Containing ART Does Not Reduce Combined Oral Contraceptive Effectiveness (January/February 2013)
  To read PDF, click here.
• Minimal Risk of Sexual HIV Transmission for Heterosexual Couples When the HIV-Positive Partner Has an Undetectable Viral Load (January/February 2013)
  To read PDF, click here.
• Differences by Age for Women in Response to Initial ART: Meta-Analysis From Clinical Studies Submitted to the FDA (January/February 2013)
  To read PDF, click here.
• Lopinavir/Ritonavir in Pregnancy: Results From a Systematic Review (January/February 2013)
  To read PDF, click here.
• Possible Mechanisms for Adverse Pregnancy Outcomes in HIV-Positive Women (January/February 2013)
  To read PDF, click here.
• Pediatric TB/HIV Coinfection: Glimpses of Pharmacokinetic Data and a Potential New Approach to Drug Development (January/February 2013)
  To read PDF, click here.
• Low Bone Mineral Density in MSM Irrespective of HIV Status (January/February 2013)
  To read PDF, click here.
• UK Group Describe Risk of HIV Transmission for People on Effective ART as "Extremely Low" (January/February 2013)
  To read PDF, click here.
• Poster on the Immune Response to HIV (January/February 2013)
  To read PDF, click here.
• Issues That Divide Expert Opinion: When to Start, HIV and Aging and the Impact of HIV on Life Expectancy (November/December 2012)
  To read PDF, click here.
• Dolutegravir: Integrase Resistance and the Impact of the Background Regimen (November/December 2012)
  To read PDF, click here.
• Updated Results on Quad: 96-Week Data From Phase 3 Studies (November/December 2012)
  To read PDF, click here.
• HIV/HCV Coinfection: Early Glimpses of an Interferon-Free Future and EuroSIDA Incidence Data (November/December 2012)
  To read PDF, click here.
• Resistance in Infants and Children Receiving ART in South Africa (November/December 2012)
  To read PDF, click here.
• Cure Rates With Pipeline HCV Drugs: Reports From AASLD (November/December 2012)
  To read PDF, click here.
• FDA Approval of Generic ARVs (November/December 2012)
  To read PDF, click here.
• d4T -- Time to Move On (November/December 2012)
  To read PDF, click here.
• Global Fund Provides ART for 4.2 Million People: 2012 Update (November/December 2012)
  To read PDF, click here.
• $84-Million Grant to Zimbabwe to Reach Universal Access in 2012 (November/December 2012)
  To read PDF, click here.
• U.S. NIH to Enforce Open Access to Clincal Trial Results (November/December 2012)
  To read PDF, click here.
• The Challenge of Adherence During Pregnancy and After (November/December 2012)
  To read PDF, click here.
• ART and Adverse Birth Outcomes in Botswana (November/December 2012)
  To read PDF, click here.
• UK Standards for HIV Care Launched by BHIVA (November/December 2012)
  To read PDF, click here.
• Low Incidence of Liver-Related Deaths in HIV-Positive People Without HBV and/or HCV Coinfection (November/December 2012)
  To read PDF, click here.
• Rapid Drop in Mitochondria in Fat Biopsies Within Four Weeks of d4T Use (November/December 2012)
  To read PDF, click here.
• High-Dose Multivitamin Use in Advanced HIV Has No Benefit to CD4 and Viral Load and May Cause Liver Toxicity (November/December 2012)
  To read PDF, click here.
• HIV in the United Kingdom: 2012 Report (November/December 2012)
  To read PDF, click here.
• Study Summaries From ICAAC 2012 (September/October 2012)
• Antiviral Activity In Vitro With S/GSK1265744 (September/October 2012)
• Efavirenz Interaction Studies With TB Compounds Bedaquiline and Delamanid (September/October 2012)
• 52nd International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 9-12 September 2012, San Francisco (September/October 2012)
• HPTN-052: Clinical Advantages From Earlier Treatment (September/October 2012)
• Hormonal Contraception and the Risk of HIV Acquisition (September/October 2012)
• Towards an HIV Cure: Early Developments Reported at IAS, Part 2 (September/October 2012)
• FDA Approves Quad in U.S.: Price May Prohibit UK Access (September/October 2012)
• Merck Acquires CMX157 and EFdA and Starts Phase 2 Study for New NNRTI (September/October 2012)
• Roche to Discontinue Production of Nelfinavir and Saquinavir 200-mg Hard Capsules (September/October 2012)
• FDA Approval of Generic ARVs (September/October 2012)
• Free HIV Treatment in the UK for All, Irrespective of Residency Status (September/October 2012)
• Robin Hood Tax Begins in France (September/October 2012)
• Novartis Case Enters Indian Supreme Court (September/October 2012)
• UK Standards for HIV Care Online for Comment (September/October 2012)
• HIV in England to Remain as Nationally Commissioned Specialist Service (September/October 2012)
• IAS USA Update Adult ARV Treatment Guidelines (September/October 2012)
• Increased Incidence of Ischemic Stroke Amongst HIV-Positive Cohort (September/October 2012)
• Discord Controllers: Characterizing a New Viremic Controller Phenotype (September/October 2012)
• Jerome Horwitz Dies at 93 (September/October 2012)
• Skeletal Muscle Toxicity and Raltegravir (July/August 2012)
  To read PDF, click here.
• Proteinuria as a Potential Early Marker of Tenofovir-Related Renal Toxicity (July/August 2012)
  To read PDF, click here.
• Earlier and Greater Comorbidities Reported in HIV-Positive Cohort (July/August 2012)
  To read PDF, click here.
• In Vitro Resistance Profile for BMS 986001 (July/August 2012)
  To read PDF, click here.
• Recombination Dynamics in Case of MDR HIV Sub-Type D Following Superinfection With Wild-Type HIV Sub-Type B (July/August 2012)
  To read PDF, click here.
• Defective Viral Reservoir Populations Is Common in HIV Patients on Long-Term Suppressed ART (July/August 2012)
  To read PDF, click here.
• First Case Report of HIV Transmission With Five-Class Resistance (July/August 2012)
  To read PDF, click here.
• Dolutegravir Indicates Superiority Compared to Efavirenz in Treatment-Naive Patients: Top-Line Results Only (July/August 2012)
  To read PDF, click here.
• FDA Approval of Generic ARVs (July/August 2012)
  To read PDF, click here.
• Theratechnologies Withdraw EU Application for Tesamorelin (Egrifta) (July/August 2012)
  To read PDF, click here.
• Recent Studies on HIV, ART and Osteoporotic Fracture Risk (July/August 2012)
  To read PDF, click here.
• ACT-UP in Film: How to Survive a Plague and United in Anger (July/August 2012)
  To read PDF, click here.
• 19th IAS World AIDS Conference, 22-25 July 2012, Washington (July/August 2012)
  To read PDF, click here.
• IAS: Social and Political Talks Online as Web Casts (July/August 2012)
  To read PDF, click here.
• New Booster -- Cobicistat as an Alternative to Ritonavir (July/August 2012)
  To read PDF, click here.
• Dolutegravir vs. Raltegravir in Treatment-Naive Patients: 48-Week Results From the SPRING 2 Study (July/August 2012)
  To read PDF, click here.
• Elvitegravir vs. Raltegravir: 96-Week Phase III Results in Treatment-Experienced Patients (July/August 2012)
  To read PDF, click here.
• In Vitro and Animal Data Support Safety Profile BMS 986001: d4T-Like NRTI Currently in Clinical Trials (July/August 2012)
  To read PDF, click here.
• Switching to Rilpivirine/Tenofovir/FTC Fixed-Dose Combination From Boosted-PI Regimen: SPIRIT Study Draws the Line at 24 Weeks (July/August 2012)
  To read PDF, click here.
• Maraviroc Plus Atazanavir/Ritonavir in a Nuke-Sparing Regimen in Treatment-Naive Patients (July/August 2012)
  To read PDF, click here.
• Five-Year Results From Raltegravir Registrational Studies (July/August 2012)
  To read PDF, click here.
• First Report: Atazanavir-Related Gallstones (Cholelithiasis) (July/August 2012)
  To read PDF, click here.
• Pediatrics Studies at 19th International AIDS Conference and the 4th International Workshop on HIV Pediatrics (July/August 2012)
  To read PDF, click here.
• Novel Lopinavir/Ritonavir Sprinkle Formulation for Children in Resource-Limited Settings (July/August 2012)
  To read PDF, click here.
• Update on New Antiretrovirals for Children and Adolescents (July/August 2012)
  To read PDF, click here.
• Tenofovir Prophylaxis for Neonates (July/August 2012)
  To read PDF, click here.
• Efavirenz Levels Variable in Children in the CHAPAS-3 Study (July/August 2012)
  To read PDF, click here.
• Early Initiation of ART Is Associated With Growth Recovery in Children in NEVEREST-2 (July/August 2012)
  To read PDF, click here.
• High Prevalence of Peripheral Neuropathy in Children Taking d4T in Rural South Africa (July/August 2012)
  To read PDF, click here.
• Lipid Profile in Children in PREDICT: Immediate Versus Deferred Nevirapine-Based ART (July/August 2012)
  To read PDF, click here.
• High Levels of Maraviroc in Rectal Tissue Fail to Protect Macaques From SIV Transmission Following Rectal Exposure (July/August 2012)
  To read PDF, click here.
• Mechanisms for Circumcision to Reduce HIV Transmission in Different Penile Tissue: Target Cell Differences Rather Than Keratinisation (July/August 2012)
  To read PDF, click here.
• Towards an HIV Cure: Early Developments in the Field (July/August 2012)
  To read PDF, click here.
• Important Publications Launched at IAS 2012 (July/August 2012)
  To read PDF, click here.
• Washout Pharmacokinetics of Transplacental Raltegravir in Neonates (May/June 2012)
  To read PDF, click here.
• Fosamprenavir Pediatric Dosing Approved in U.S. for Ages 4 Weeks to <6 Years (May/June 2012)
  To read PDF, click here.
• NICE Guideline on Fertility Treatment Proposes Alternatives to Sperm Washing (May/June 2012)
  To read PDF, click here.
• Associations Between Tenofovir Use and Renal Complications in VA Cohort (May/June 2012)
  To read PDF, click here.
• Risk Factors Associated With End Stage Renal Disease (ESRD) in HIV-Positive Patients in the U.S. Veterans Association (VA) Cohort (May/June 2012)
  To read PDF, click here.
• 20% People Switch Atripla Due to Efavirenz Side Effects: Late Switches Are Common (May/June 2012)
  To read PDF, click here.
• FDA Approval of Generic ARVs: Nevirapine and Combivir Now Off-Patent in the U.S. (May/June 2012)
  To read PDF, click here.
• Stavudine (d4T) Phase-Out Festival in Delhi (May/June 2012)
  To read PDF, click here.
• HIV and the Brain: Longitudinal Results From CHARTER and Other Studies (May/June 2012)
  To read PDF, click here.
• Systolic Blood Pressure and Risk of Myocardial Infarction in HIV Infection (May/June 2012)
  To read PDF, click here.
• Risk of Non-AIDS-Defining Malignancies and Immune Suppression (May/June 2012)
  To read PDF, click here.
• Renal Impairment in the D:A:D Study (May/June 2012)
  To read PDF, click here.
• Early Data for Rilpivirine Long-Acting Formulation Supports Further Investigation for PrEP (May/June 2012)
  To read PDF, click here.
• Hormonal Contraception: HIV Transmission and Progression Rates (May/June 2012)
  To read PDF, click here.
• Darunavir Use During Pregnancy (May/June 2012)
  To read PDF, click here.
• Half of Gay Men in London Would Chose Oral PrEP to Reduce Risk of HIV (May/June 2012)
  To read PDF, click here.
• Recent Infection Is Common in UK; 30% Gay Men Aged 15-25 Infected Within a Year of Diagnosis (May/June 2012)
  To read PDF, click here.
• One Third of HIV-Positive People at Five UK Clinics Have Symptomatic Depression: Link to Adherence and Viral Suppression -- 40% Cases Are Untreated (May/June 2012)
  To read PDF, click here.
• Hodgkin's Lymphoma: Survival Normalizes to HIV-Negative Rates Despite More Advanced Disease at Diagnosis (May/June 2012)
  To read PDF, click here.
• Promising Outcomes From Laser Ablative Treatment of AIN2/3 to Prevent Anal Cancer (May/June 2012)
  To read PDF, click here.
• KS in the HAART Era Includes Patients With High CD4 and Suppressed Viral Load: Importance of KS Chemotherapy for Some Patients in Addition to ART (May/June 2012)
  To read PDF, click here.
• Third- vs. Fourth-Generation HIV Testing: Almost Half of UK Clinics Out of Step With National Guidelines (May/June 2012)
  To read PDF, click here.
• Case Reports of Complications From Ketamine Use in Two MSM on Ritonavir-Based Combinations (May/June 2012)
  To read PDF, click here.
• Intranasal and Topical Corticosteroids and Risk of Cushing's Symptoms in HIV Patients on Ritonavir-Based Combinations (May/June 2012)
  To read PDF, click here.
• Outcomes From Switches to Atazanavir/r in London (May/June 2012)
  To read PDF, click here.
• Intimate Partner Violence Towards HIV-Positive Women in the UK (May/June 2012)
  To read PDF, click here.
• Studies on Pipeline ARVs: Quad, Evitegravir/Cobicistat, Cobicistat, GSK1265744, BMS986001 Dolutegravir, GSK-1265744, Long-Acting Formulations (Monthly Injections): Rilpivirine-LA, Raltegravir and Patient Views (May/June 2012)
  To read PDF, click here.
• Warfarin and ARVs: Impact of African-American Race and Ritonavir (May/June 2012)
  To read PDF, click here.
• Cure Research Takes Center Stage: Proof of Concept for Activating the Latent Reservoir (March/April 2012)
  To read PDF, click here.
• Quad Fixed-Dose Integrase Combination: Phase 3 Studies at Week 48 (March/April 2012)
  To read PDF, click here.
• Dolutegravir Studies Continue to Show Promise (March/April 2012)
  To read PDF, click here.
• PrEP: PK Modeling of Daily TDF/FTC (Truvada) Provides Close to 100% Protection Against HIV Infection (March/April 2012)
  To read PDF, click here.
• Tenofovir Prodrug: 10-Day Monotherapy Study Sets Dose at 25 mg for Easier Coformulation (March/April 2012)
  To read PDF, click here.
• Pediatric Formulations of ARVs: Including an Exciting New Class (March/April 2012)
  To read PDF, click here.
• Lower Malaria Risk in Children Receiving Lopinavir/Ritonavir-Based Compared to NNRTI-Based ART (March/April 2012)
  To read PDF, click here.
• Lopinavir/Ritonavir Monotherapy in Children (March/April 2012)
  To read PDF, click here.
• High Prevalence of d4T-Associated Lipodystrophy Including Lipoatrophy in Children (March/April 2012)
  To read PDF, click here.
• Stopping Treatment After Early ART in Infants (March/April 2012)
  To read PDF, click here.
• Risk of HIV Reinfection May Be Similar to Risk of Initial HIV Infection (March/April 2012)
  To read PDF, click here.
• Case Report: Homozygous CCR5 Delta-32 Protection Overcome by Infection With X4 Virus (March/April 2012)
  To read PDF, click here.
• No Association Between Atazanavir and MI or Stroke in D:A:D Study (March/April 2012)
  To read PDF, click here.
• Hepatitis C Coinfection Studies (March/April 2012)
  To read PDF, click here.
• Herpes Zoster Vaccine Safe and Effective in HIV-Positive People (March/April 2012)
  To read PDF, click here.
• High-Dose Flu Vaccine Improves Antibody Responses in HIV-Positive People (March/April 2012)
  To read PDF, click here.
• Dolutegravir Expanded Access Program (March/April 2012)
  To read PDF, click here.
• Global Action Over the Challenge to India's Patent Laws (March/April 2012)
  To read PDF, click here.
• FDA Rejects Capsaicin Patch for HIV-Related Neuropathy (March/April 2012)
  To read PDF, click here.
• US HHS Adult Treatment Guidelines Updated; Comparison With UK BHIVA Guidelines (March/April 2012)
  To read PDF, click here.
• Similar Efficacy and a Few Gender-Related Differences in Side Effects With Rilpivirine Versus Efavirenz at 96 Weeks (January/February 2012)
  To read PDF, click here.
• The Effect of BMI on Efficacy, Safety and Tolerability of Lopinavir/r in Women (January/February 2012)
  To read PDF, click here.
• Hormonal Contraception and Higher Risk of Non-AIDS-Defining Events in Nashville Cohort (January/February 2012)
  To read PDF, click here.
• Poorer Adherence and Loss to Follow Up in Kenyan Women Who Are Pregnant When Enrolled to ART Programs (January/February 2012)
  To read PDF, click here.
• Workshop Report and Commentary (January/February 2012)
  5th HIV Persistence Workshop on HIV Reservoirs, 6-9 December 2011, West Indies.
  To read PDF, click here.
• Nevirapine Prolonged Release Once-Daily Formulation Available in the UK (January/February 2012)
  To read PDF, click here.
• Etravirine 200-mg Formulation Available in UK (January/February 2012)
  To read PDF, click here.
• Tenofovir Label Extended to Pediatric Indication (January/February 2012)
  To read PDF, click here.
• FDA Approve U.S. Pediatric Dose for Raltegravir (January/February 2012)
  To read PDF, click here.
• FDA Approve Pediatric Dose for Darunavir (January/February 2012)
  To read PDF, click here.
• Efavirenz Dose Increase to 800 mg QD With Rifampin in Patients >50 kg (January/February 2012)
  To read PDF, click here.
• Draft BHIVA ARV Treatment Guidelines Online for Comment Until 5 March (January/February 2012)
  To read PDF, click here.
• BHIVA Guidelines for the Routine Investigation and Monitoring of Adult HIV-1-Infected Individuals 2011 (January/February 2012)
  To read PDF, click here.
• Draft BHIVA Pregnancy Guidelines Online for Comment Until 5 March (January/February 2012)
  To read PDF, click here.
• Delaying ART in Childhood Can Reduce Long-Term CD4 Count in Adulthood (January/February 2012)
  To read PDF, click here.
• Need for Expanded Access to Two Promising MDR TB Drugs (January/February 2012)
  To read PDF, click here.
• No Increased Risk of Non-AIDS Deaths From Cumulative Use of ART in EuroSIDA Cohort (January/February 2012)
  To read PDF, click here.
• FDA Approval of Generic ARVs (January/February 2012)
  To read PDF, click here.
• Disastrous Warning for Global HIV Programs in 2012 (January/February 2012)
  To read PDF, click here.
• Block Patent Pool Access to Darunavir, Rilpivirine and Etravrine (January/February 2012)
  To read PDF, click here.
• UNITAID Continues Funding the Patent Pool, Pediatric HIV Medicines and Malaria (January/February 2012)
  To read PDF, click here.
• Activists Oppose Gates Foundation Funding Study Using Low-Dose d4T (January/February 2012)
  To read PDF, click here.
• Testosterone: A Man's Guide: Practical Tips for Boosting Physical, Mental and Sexual Vitality by Nelson Vergel (January/February 2012)
  To read PDF, click here.
• FDA Approve New NNRTI Rilpivirine (Edurant) in the U.S. (July/August 2011)
  To read PDF, click here.
• FDA Approve New NNRTI-Based Fixed-Dose Combination of Rilpivirine/Tenofovir/FTC (Complera) in the U.S. (July/August 2011)
  To read PDF, click here.
• FDA Approve Boceprevir (Victrelis) for HCV (July/August 2011)
  To read PDF, click here.
• FDA Approve Telaprevir (Incivek) to Treat Hepatitis C (July/August 2011)
  To read PDF, click here.
• FDA Supplemental Information About Using Boceprevir and Telaprevir (July/August 2011)
  To read PDF, click here.
• Dolutegravir (S/GSK1349572) With Multivitamins or Acid Reducing Agents (July/August 2011)
  To read PDF, click here.
• Lopinavir and Rifampicin Interaction in HIV-Positive Patients (July/August 2011)
  To read PDF, click here.
• Case Reports: Cushing's Syndrome With Atazanavir/Ritonavir (July/August 2011)
  To read PDF, click here.
• Gilead Signs Up for Medicines Patent Pool (July/August 2011)
  To read PDF, click here.
• FDA Approval of Generic ARVs (July/August 2011)
  To read PDF, click here.
• HPTN 052 Study Stopped Early: Significant Reduction in HIV Transmission From Early Use of HIV Treatment in Serodifferent Partners (July/August 2011)
  To read PDF, click here.
• Treatment in Seroconversion Maintains HIV-Specific Immune Responses Similar to Long-Term Slow Progressors (July/August 2011)
  To read PDF, click here.
• Monitoring Treatment in Resource-Limited Settings: Results From PHPT-3 and Stratall ANRS12110/ESTER Trials (July/August 2011)
  To read PDF, click here.
• DART: High Rates of Viral Suppression After Five Years and a Single CD4 Test With a Threshold of 250 Cells/mm³ Could Reduce Unnecessary Switching (July/August 2011)
  To read PDF, click here.
• Lopinavir/r Monotherapy Used as Second-Line Therapy in Resource-Limited Settings (July/August 2011)
  To read PDF, click here.
• Treating Children Previously Exposed to Single Dose Nevirapine: Update on IMPAACT P1060 and NEVEREST (July/August 2011)
  To read PDF, click here.
• Lopinavir/Ritonavir Oral Solution Toxicity in Neonates (July/August 2011)
  To read PDF, click here.
• Paediatric Antiretroviral Pipeline: Darunavir and Raltegravir (July/August 2011)
  To read PDF, click here.
• Pharmacokinetics of Different Rifabutin Dosing Strategies With Lopinavir/Ritonavir-Based ART (July/August 2011)
  To read PDF, click here.
• Initiation of ART During Breastfeeding Can Induce Multidrug Resistance in Infants (July/August 2011)
  To read PDF, click here.
• Webcasts for Major Research at IAS 2011 (July/August 2011)
  To read PDF, click here.
• Treatment Is Prevention: ARV Treatment in HPTN-052 Reduces Transmission by at Least 96%: Single Transmission in Treatment Arm Occurred Prior to Viral Suppression (July/August 2011)
  To read PDF, click here.
• Daily Oral Tenofovir/FTC PrEP Reduces Heterosexual Transmission by 63% in the TDF2 Study (July/August 2011)
  To read PDF, click here.
• Tenofovir/FTC vs. Tenofovir as Daily Oral PrEP: Preliminary Results From Partners PrEP (July/August 2011)
  To read PDF, click here.
• Elvitegravir vs. Raltegravir: 48-Week Results in Treatment-Experienced Patients (July/August 2011)
  To read PDF, click here.
• Dolutegravir: 48-Week Results From Phase II Study in Treatment-Naive Patients (July/August 2011)
  To read PDF, click here.
• Lersivirine: 48-Week Results Compared to Efavirenz in Phase 2 Treatment-Naive Study (July/August 2011)
  To read PDF, click here.
• Maraviroc Plus Atazanavir/r Without Nukes Versus Standard of Care: 48-Week Results (July/August 2011)
  To read PDF, click here.
• SPARTAC Trial: Treatment in Primary Infection for 48 Weeks Shows Small Delay in Disease Progression (July/August 2011)
  To read PDF, click here.
• Hearing Loss Not Associated With HIV in MACS and WIHS Cohorts (July/August 2011)
  To read PDF, click here.
• Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy (July/August 2011)
  To read PDF, click here.
• Low Birth Weight and Preterm Delivery (July/August 2011)
  To read PDF, click here.
• Hormonal Contraception and HIV Transmission Risk (July/August 2011)
  To read PDF, click here.
• No Difference in AIDS-Free Survival in Children Starting ART With a CD4% Between 15%-24% Compared to Deferring Until Less Than 15% in the PREDICT Trial (July/August 2011)
  To read PDF, click here.
• Paediatric Antiretroviral Pipeline: Update on Etravirine and Maraviroc (July/August 2011)
  To read PDF, click here.
• Prematurity Not Associated With Early Mortality in Infants on ART (July/August 2011)
  To read PDF, click here.
• More Metabolic Abnormalities in Children Receiving a PI Compared to NNRTI in NEVEREST Study (July/August 2011)
  To read PDF, click here.
• Free Online Resource for Treatment Decisions Without Access to Genotype Resistance Tests (July/August 2011)
  To read PDF, click here.
• Quad Reduces Levels of Oral Contraceptives (May/June 2011)
  To read PDF, click here.
• Elvitegravir/Cobicistat and Acid Reducing Agents (May/June 2011)
  To read PDF, click here.
• Lopinavir/r Reduces Levels of Rifabutin (May/June 2011)
  To read PDF, click here.
• Cobicistat Has Little Impact on CYP2D6 and CYP2B6 (May/June 2011)
  To read PDF, click here.
• Atazanavir Levels Indicate Need for Higher Dose During Pregnancy (May/June 2011)
  To read PDF, click here.
• Once-Daily 150-mg Maraviroc Explored in People Taking Atazanavir/Ritonavir (May/June 2011)
  To read PDF, click here.
• Lopinavir Troughs Lower in Children on Once-Daily Dose With Efavirenz (May/June 2011)
  To read PDF, click here.
• Dose Optimisation: 50 mg Ritonavir-Boosting, 3TC Dosing and Raltegravir Once-Daily (May/June 2011)
  To read PDF, click here.
• Etravirine Lowers Levels of Maraviroc Given at 300 or 600 mg Twice Daily (May/June 2011)
  To read PDF, click here.
• Atazanavir in Pregnancy: 155 Cases in London Clinics (May/June 2011)
  To read PDF, click here.
• Co-Morbidity and Late Presentation -- Findings From an Over 50s Cohort (May/June 2011)
  To read PDF, click here.
• Health Outcomes for Young Adults With Perinatally Acquired HIV Infection Following Transfer to Adult Services (May/June 2011)
  To read PDF, click here.
• The Use of Calcaneal Stiffness Index to Screen for Osteoporosis in HIV-Infected Individuals (May/June 2011)
  To read PDF, click here.
• Frequency and Characteristics of Long-Term Non-Progressors and HIV Controllers in the Chelsea and Westminster Cohort (May/June 2011)
  To read PDF, click here.
• Cerebral Function in Perinatally HIV Infected Young People and HIV Uninfected Sibling Controls (May/June 2011)
  To read PDF, click here.
• An Audit of HIV Care Provision for Immigration Removal Centre (May/June 2011)
  To read PDF, click here.
• BASHH/BHIVA PEPSE Guidelines for Comment (May/June 2011)
  To read PDF, click here.
• UK National Guideline on Safer Sex Advice (May/June 2011)
  To read PDF, click here.
• Rapid Report: State of HCV Policy, Treatment, Access (May/June 2011)
  To read PDF, click here.
• Inflammation and Intervention: How Does HIV Cause AIDS and How Does It Cause Disease Despite ART (May/June 2011)
  To read PDF, click here.
• When to Start ART in Patients Co-Infected With TB: Results From Two Trials Presented at CROI (May/June 2011)
  To read PDF, click here.
• First Workshop on Nanomedicine for Infectious Diseases of Poverty, 27�31 March 2011, Magaliesberg, South Africa (May/June 2011)
  To read PDF, click here.
• London HIV Consortium Issues New Guidelines for ARV Prescribing (March/April 2011)
  To read PDF, click here.
• European Medicines Agency Issues Restricted Indication for d4T (Stavudine) (March/April 2011)
  To read PDF, click here.
• Changes to Starting Dose of Saquinavir in Naive Patients (March/April 2011)
  To read PDF, click here.
• FDA Approves Nevirapine XR (March/April 2011)
  To read PDF, click here.
• Lopinavir/r Oral Solution (March/April 2011)
  To read PDF, click here.
• Atazanavir Use During Pregnancy (March/April 2011)
  To read PDF, click here.
• Nelfinavir Interaction With Warfarin (March/April 2011)
  To read PDF, click here.
• New Antiretrovirals: Dolutegravir, Entry Inhibitor (BMS-663068) and Tenofovir Pro-Drug (GS-7340) (March/April 2011)
  To read PDF, click here.
• Immune-Based Treatment Increases HIV-Resistant CD4 Cells in Phase 1 Study (March/April 2011)
  To read PDF, click here.
• Antiretroviral Prevention: Oral PrEP, Gels and Treatment Studies (March/April 2011)
  To read PDF, click here.
• Further Efficacy Analyses From the iPrEx Study (March/April 2011)
  To read PDF, click here.
• Topical Gels as PEP and PrEP: Animal and Human Studies (March/April 2011)
  To read PDF, click here.
• Maternal Risk Following Short Course HAART (March/April 2011)
  To read PDF, click here.
• Pre-Term Delivery and HAART (March/April 2011)
  To read PDF, click here.
• HAART More Effective Than AZT Monotherapy in the Botswana PMTCT Programme (March/April 2011)
  To read PDF, click here.
• Lopinavir/r Monotherapy for PMTCT (March/April 2011)
  To read PDF, click here.
• No Evidence of Increased Risk of MTCT With Sequential Pregnancies in UK and Ireland (March/April 2011)
  To read PDF, click here.
• Recently Infected Women at the Time of Delivery Have a Higher Rate of In-Utero Transmission in PEPI-Malawi (March/April 2011)
  To read PDF, click here.
• Reduced CCL22 Concentrations in Cervicovaginal Secretions From Pregnant Women (March/April 2011)
  To read PDF, click here.
• First Results From Telaprevir in HIV/HCV Coinfection (March/April 2011)
  To read PDF, click here.
• HCV Reinfection Rates in HIV-Positive Gay Men (March/April 2011)
  To read PDF, click here.
• Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (November/December 2008)